Seattle Genetics, Inc. (OQ:SGEN)

Business Focus: Biotechnology & Medical Research

INK Ultra Money Free

Latest 10 SEC filings (by transaction date) for SGEN within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET January 18th, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Jan 10/20 Jan 8/20 Siegall Clay B Direct Ownership Non-Qualified Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -27,153  
Jan 10/20 Jan 8/20 Siegall Clay B Direct Ownership Non-Qualified Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -1,319  
Jan 10/20 Jan 8/20 Siegall Clay B Direct Ownership Common Stock S - Open market or private sale -27,153 $111.28
Jan 10/20 Jan 8/20 Siegall Clay B Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 27,153 $12.00
Jan 10/20 Jan 8/20 Siegall Clay B Direct Ownership Common Stock S - Open market or private sale -1,319 $112.09
Jan 10/20 Jan 8/20 Siegall Clay B Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 1,319 $12.00
Jan 9/20 Jan 7/20 Welch Daniel G Direct Ownership Non-Qualified Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -17,500  
Jan 9/20 Jan 7/20 Welch Daniel G Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 17,500 $12.76
Dec 23/19 Dec 19/19 Simpson Todd E Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 871  
Dec 23/19 Dec 19/19 Himes Vaughn B Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 871  
Sign up or login above to see all SEC filings within the past 6 months.
Latest 10 SEC filings (by filing date) for SGEN within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET January 18th, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Jan 10/20 Jan 8/20 Siegall Clay B Direct Ownership Non-Qualified Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -27,153  
Jan 10/20 Jan 8/20 Siegall Clay B Direct Ownership Non-Qualified Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -1,319  
Jan 10/20 Jan 8/20 Siegall Clay B Direct Ownership Common Stock S - Open market or private sale -27,153 $111.28
Jan 10/20 Jan 8/20 Siegall Clay B Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 27,153 $12.00
Jan 10/20 Jan 8/20 Siegall Clay B Direct Ownership Common Stock S - Open market or private sale -1,319 $112.09
Jan 10/20 Jan 8/20 Siegall Clay B Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 1,319 $12.00
Jan 9/20 Jan 7/20 Welch Daniel G Direct Ownership Non-Qualified Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -17,500  
Jan 9/20 Jan 7/20 Welch Daniel G Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 17,500 $12.76
Dec 23/19 Dec 19/19 Simpson Todd E Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 871  
Dec 23/19 Dec 19/19 Himes Vaughn B Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 871  
Sign up or login above to see all SEC filings within the past 6 months.
Sign up or login above to see the past 6 months of filings sorted by insider. .
Get holdings trends & enhanced insider charts in PDF now

Twitter

Search (past week) for $SGEN

Competitors

Competitors with Recent Insider Filings
Iqvia Holdings (N:IQV)
Vir Biotechnology (OQ:VIR)
ACADIA Pharmaceuticals (OQ:ACAD)